Merck, Inc.
🇵🇭Philippines
A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
Phase 2
Terminated
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT00239655
Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 89
- Registration Number
- NCT00237484
A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2015-12-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 848
- Registration Number
- NCT00231790
A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 216
- Registration Number
- NCT00231777
A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2015-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 763
- Registration Number
- NCT00231816
Comparison of SCH 486757 to Codeine and Placebo in Subjects With Persistent Postviral Cough (Study P03069AM2)(COMPLETED)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2015-09-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 91
- Registration Number
- NCT00230230
Historical Control Study of Refractory IFI or Patients Intolerant to Standard Antifungal Therapy in Patients With Invasive Fungal Infections (Study P02387)
Completed
- Conditions
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 330
- Registration Number
- NCT00230243
Comparative Study of Ertapenem Versus Another Antibiotic in the Treatment of Diabetic Foot Infections in Adults (0826-034)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 400
- Registration Number
- NCT00229112
Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00227435
A Study in Subjects With Perennial Allergic Rhinitis
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 630
- Registration Number
- NCT00210015
© Copyright 2024. All Rights Reserved by MedPath